CN1556706A - 具有脂肪酶抑制活性的噻吩并-(1,3)-噁嗪-4-酮 - Google Patents
具有脂肪酶抑制活性的噻吩并-(1,3)-噁嗪-4-酮 Download PDFInfo
- Publication number
- CN1556706A CN1556706A CNA028185900A CN02818590A CN1556706A CN 1556706 A CN1556706 A CN 1556706A CN A028185900 A CNA028185900 A CN A028185900A CN 02818590 A CN02818590 A CN 02818590A CN 1556706 A CN1556706 A CN 1556706A
- Authority
- CN
- China
- Prior art keywords
- ketone
- thieno
- oxazine
- phenyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cosmetics (AREA)
- Detergent Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
Claims (31)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0121019A GB0121019D0 (en) | 2001-08-30 | 2001-08-30 | /nhibitors |
GB0121019.4 | 2001-08-30 | ||
GB0206031A GB0206031D0 (en) | 2002-03-14 | 2002-03-14 | Inhibitors |
GB0206031.7 | 2002-03-14 | ||
PCT/GB2002/003903 WO2003020282A1 (en) | 2001-08-30 | 2002-08-23 | Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1556706A true CN1556706A (zh) | 2004-12-22 |
CN1556706B CN1556706B (zh) | 2011-04-27 |
Family
ID=26246489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN028185900A Expired - Fee Related CN1556706B (zh) | 2001-08-30 | 2002-08-23 | 具有脂肪酶抑制活性的噻吩并-(1,3)-噁嗪-4-酮 |
Country Status (20)
Country | Link |
---|---|
US (2) | US7407954B2 (zh) |
EP (1) | EP1446125B1 (zh) |
JP (2) | JP2005527469A (zh) |
KR (1) | KR100934256B1 (zh) |
CN (1) | CN1556706B (zh) |
AR (1) | AR036399A1 (zh) |
AT (1) | ATE429918T1 (zh) |
AU (1) | AU2002321536B2 (zh) |
CA (1) | CA2458213A1 (zh) |
DE (1) | DE60232170D1 (zh) |
HK (1) | HK1064940A1 (zh) |
HU (1) | HUP0401298A3 (zh) |
MX (1) | MXPA04001922A (zh) |
MY (1) | MY139608A (zh) |
NO (1) | NO20041295L (zh) |
NZ (1) | NZ531272A (zh) |
PL (1) | PL368994A1 (zh) |
RU (1) | RU2324696C2 (zh) |
WO (1) | WO2003020282A1 (zh) |
ZA (1) | ZA200401595B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA04001922A (es) * | 2001-08-30 | 2005-03-07 | Alizyme Therapeutics Ltd | Tieno-(1,3)-oxazin-4-onas con actividad inhibidora de lipasa. |
AU2002366810B2 (en) * | 2001-12-20 | 2009-06-11 | Osi Pharmaceuticals, Inc. | Pancreatic lipase inhibitor compounds, their synthesis and use |
US20090143411A1 (en) * | 2004-10-20 | 2009-06-04 | Compass Pharmaceuticals Llc | Thiophens and Their Use as Anti-Tumor Agents |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1247547A (en) * | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
DE3540377A1 (de) * | 1985-11-14 | 1987-05-21 | Bayer Ag | Thienooxazinone, verfahren zu ihrer herstellung und ihre verwendung als leistungsfoerderer |
IL125947A0 (en) | 1997-09-17 | 1999-04-11 | American Cyanamid Co | 3-(1,2-benzisothiazol- and isoxazol-5-yl)-2,4(1h,3h)-pyrimidinedione or thione and 3-(1,2-benzisothiazol- and isoxazol-5-yl)-4(3)-pyrimidinone or thione herbicidal agents |
EP0985670A1 (en) | 1998-08-13 | 2000-03-15 | American Cyanamid Company | 1-(3-Heterocyclylphenyl)isothiourea, -isourea, -guanidine and -amidine compounds as herbicides |
AU1375000A (en) | 1998-11-26 | 2000-06-13 | Novo Nordisk A/S | Heterocyclic compounds regulating clotting |
AR022204A1 (es) * | 1999-01-08 | 2002-09-04 | Norgine Bv | Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende. |
GB9900416D0 (en) * | 1999-01-08 | 1999-02-24 | Alizyme Therapeutics Ltd | Inhibitors |
JP2003509538A (ja) * | 1999-09-10 | 2003-03-11 | ザ、プロクター、エンド、ギャンブル、カンパニー | 酵素インヒビター |
GB0001572D0 (en) * | 2000-01-24 | 2000-03-15 | Alizyme Therapeutics Ltd | Inhibitors |
JP2002105081A (ja) | 2000-07-28 | 2002-04-10 | Nikken Chem Co Ltd | 新規チオフェンニ環化合物 |
MXPA04001922A (es) * | 2001-08-30 | 2005-03-07 | Alizyme Therapeutics Ltd | Tieno-(1,3)-oxazin-4-onas con actividad inhibidora de lipasa. |
AU2002366810B2 (en) | 2001-12-20 | 2009-06-11 | Osi Pharmaceuticals, Inc. | Pancreatic lipase inhibitor compounds, their synthesis and use |
-
2002
- 2002-08-23 MX MXPA04001922A patent/MXPA04001922A/es active IP Right Grant
- 2002-08-23 PL PL02368994A patent/PL368994A1/xx not_active Application Discontinuation
- 2002-08-23 JP JP2003524589A patent/JP2005527469A/ja not_active Withdrawn
- 2002-08-23 EP EP02755241A patent/EP1446125B1/en not_active Expired - Lifetime
- 2002-08-23 DE DE60232170T patent/DE60232170D1/de not_active Expired - Lifetime
- 2002-08-23 KR KR1020047002805A patent/KR100934256B1/ko not_active IP Right Cessation
- 2002-08-23 CA CA002458213A patent/CA2458213A1/en not_active Abandoned
- 2002-08-23 US US10/488,045 patent/US7407954B2/en not_active Expired - Fee Related
- 2002-08-23 AU AU2002321536A patent/AU2002321536B2/en not_active Ceased
- 2002-08-23 WO PCT/GB2002/003903 patent/WO2003020282A1/en active IP Right Grant
- 2002-08-23 AT AT02755241T patent/ATE429918T1/de not_active IP Right Cessation
- 2002-08-23 NZ NZ531272A patent/NZ531272A/en not_active IP Right Cessation
- 2002-08-23 HU HU0401298A patent/HUP0401298A3/hu unknown
- 2002-08-23 RU RU2004109588/04A patent/RU2324696C2/ru not_active IP Right Cessation
- 2002-08-23 CN CN028185900A patent/CN1556706B/zh not_active Expired - Fee Related
- 2002-08-29 MY MYPI20023211A patent/MY139608A/en unknown
- 2002-08-30 AR ARP020103295A patent/AR036399A1/es unknown
-
2004
- 2004-02-25 ZA ZA2004/01595A patent/ZA200401595B/en unknown
- 2004-03-29 NO NO20041295A patent/NO20041295L/no not_active Application Discontinuation
- 2004-10-07 HK HK04107740.4A patent/HK1064940A1/xx not_active IP Right Cessation
-
2008
- 2008-07-24 US US12/178,920 patent/US20090029978A1/en not_active Abandoned
-
2010
- 2010-01-29 JP JP2010019160A patent/JP2010159260A/ja not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
NO20041295L (no) | 2004-03-29 |
HUP0401298A2 (hu) | 2004-10-28 |
EP1446125A1 (en) | 2004-08-18 |
US20050075336A1 (en) | 2005-04-07 |
EP1446125B1 (en) | 2009-04-29 |
KR100934256B1 (ko) | 2009-12-28 |
KR20040052216A (ko) | 2004-06-22 |
US7407954B2 (en) | 2008-08-05 |
JP2010159260A (ja) | 2010-07-22 |
US20090029978A1 (en) | 2009-01-29 |
CA2458213A1 (en) | 2003-03-13 |
AR036399A1 (es) | 2004-09-08 |
DE60232170D1 (de) | 2009-06-10 |
ATE429918T1 (de) | 2009-05-15 |
MY139608A (en) | 2009-10-30 |
WO2003020282A1 (en) | 2003-03-13 |
RU2004109588A (ru) | 2005-05-10 |
ZA200401595B (en) | 2005-05-25 |
MXPA04001922A (es) | 2005-03-07 |
AU2002321536B2 (en) | 2007-05-17 |
RU2324696C2 (ru) | 2008-05-20 |
JP2005527469A (ja) | 2005-09-15 |
HUP0401298A3 (en) | 2008-03-28 |
PL368994A1 (en) | 2005-04-04 |
HK1064940A1 (en) | 2005-02-08 |
CN1556706B (zh) | 2011-04-27 |
NZ531272A (en) | 2006-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1915981A (zh) | 治疗肥胖症的2-氧-4h-3,1-苯并噁嗪-4-酮 | |
CN1354747A (zh) | 治疗肥胖症的2-氨基-4h-3,1-苯并噁嗪-4-酮衍生物 | |
CN100347170C (zh) | 具有dpp-iv抑制活性的氮杂二环辛烷与壬烷衍生物 | |
CN1070481C (zh) | 二氧代吗啉类化合物防治体内寄生虫的应用、新的二氧代吗啉类化合物及其制备 | |
US7759376B2 (en) | Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity | |
CN1059674C (zh) | 降低血脂的苯并硫氮杂䓬 | |
CN1143852C (zh) | 茚并、萘并和苯并芳庚并二氢噻唑衍生物、它们的制备和它们作为减食欲药物的用途 | |
CN1250549C (zh) | 吲哚衍生物及其作为5-ht2b和5-ht2c受体配体的应用 | |
CN1914180A (zh) | 作为激素敏感性脂肪酶抑制剂的吲唑衍生物 | |
JP2010514828A (ja) | ピペリジンgpcrアゴニスト | |
CN1015057B (zh) | 哌嗪基-杂环化合物的制备方法 | |
CN1321152A (zh) | 作为hPPARγ和hPPARα激活剂的取代的噁唑和噻唑衍生物 | |
CN1045776C (zh) | 吡啶环取代的噻唑烷和噁唑烷以及它们作为降血糖药的用途 | |
CN1771234A (zh) | 吡咯并三嗪激酶抑制剂的制备方法 | |
CN1688555A (zh) | 新的二环类激素敏感性脂酶抑制剂 | |
CN1167764A (zh) | 苯并吖嗪衍生物或其盐和含有它们的药物组合物 | |
CN100497323C (zh) | 新的杂环肟化合物、它们的制备方法和含有它们的药物组合物 | |
US20140364393A1 (en) | Substituted piperidinyl-carboxamide derivatives useful as scd 1 inhibitors | |
CN1556706A (zh) | 具有脂肪酶抑制活性的噻吩并-(1,3)-噁嗪-4-酮 | |
CN1483035A (zh) | 氨磺酰基噻吩并嘧啶 | |
CN1245400C (zh) | N-取代苯并噻唑磺胺衍生物 | |
CN1562970A (zh) | 具有优异降糖降酯活性的芳烷基氨基酸类ppar全激活剂 | |
CN1861560A (zh) | 一类羧酸衍生物,其制备方法及药物组合物 | |
CN1887875A (zh) | 哒嗪胺衍生物及其用于制备小rna病毒抑制剂的用途 | |
CN1111634A (zh) | 噻吩并噻嗪衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: ROGENY CO., LTD. Free format text: FORMER OWNER: ALICIMO THERAPEUTICS CO., LTD. Effective date: 20091218 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20091218 Address after: Amsterdam Applicant after: Alizyme Therapeutics Ltd. Address before: cambridge Applicant before: Alizyme Therapeutics Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110427 Termination date: 20140823 |
|
EXPY | Termination of patent right or utility model |